

Liang Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4103292/publications.pdf>

Version: 2024-02-01

18
papers

3,162
citations

759233

12
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

5274
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). <i>Annals of Translational Medicine</i> , 2022, 10, 229-229.	1.7	25
2	Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). <i>Frontiers in Oncology</i> , 2022, 12, 831345.	2.8	18
3	CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. <i>Cell Death and Disease</i> , 2022, 13, 441.	6.3	18
4	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	2
5	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. <i>Frontiers in Immunology</i> , 2021, 12, 779248.	4.8	3
6	The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study. <i>Frontiers in Immunology</i> , 2021, 12, 772450.	4.8	42
7	Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 244.	17.1	10
8	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. <i>Cell Death and Disease</i> , 2019, 10, 475.	6.3	16
9	Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting <i>ONECUT2</i> . <i>Cancer Research</i> , 2019, 79, 3608-3621.	0.9	129
10	Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. <i>Clinical Cancer Research</i> , 2018, 24, 2370-2382.	7.0	39
11	Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. <i>Nature Cell Biology</i> , 2018, 20, 597-609.	10.3	306
12	Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2018, 25, 1160-1173.	11.2	51
13	Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway. <i>Molecular Immunology</i> , 2017, 81, 102-107.	2.2	11
14	Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. <i>Frontiers in Immunology</i> , 2017, 8, 404.	4.8	73
15	Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. <i>Nature Cell Biology</i> , 2015, 17, 183-194.	10.3	895
16	TGF β 2 Induces BRCAness and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes. <i>Molecular Cancer Research</i> , 2014, 12, 1597-1609.	3.4	56
17	Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. <i>Cancer Cell</i> , 2014, 25, 501-515.	16.8	1,198
18	Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF- κ B. <i>Scientific Reports</i> , 2014, 4, 5750.	3.3	270